- Home
- IMMX vs RPHM Comparison
IMMX vs RPHM Comparison
Compare IMMX & RPHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- RPHM
- Stock Information
- Founded
- IMMX 2014
- RPHM 2014
- Country
- IMMX United States
- RPHM United States
- Employees
- IMMX N/A
- RPHM N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- RPHM Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- RPHM Health Care
- Exchange
- IMMX Nasdaq
- RPHM Nasdaq
- Market Cap
- IMMX 51.1M
- RPHM 47.5M
- IPO Year
- IMMX 2021
- RPHM 2021
- Fundamental
- Price
- IMMX $1.42
- RPHM $18.20
- Analyst Decision
- IMMX Strong Buy
- RPHM Hold
- Analyst Count
- IMMX 1
- RPHM 6
- Target Price
- IMMX $7.00
- RPHM $2.26
- AVG Volume (30 Days)
- IMMX 144.1K
- RPHM 345.4K
- Earning Date
- IMMX 11-11-2024
- RPHM 11-11-2024
- Dividend Yield
- IMMX N/A
- RPHM N/A
- EPS Growth
- IMMX N/A
- RPHM N/A
- EPS
- IMMX N/A
- RPHM N/A
- Revenue
- IMMX N/A
- RPHM N/A
- Revenue This Year
- IMMX N/A
- RPHM N/A
- Revenue Next Year
- IMMX $200.00
- RPHM N/A
- P/E Ratio
- IMMX N/A
- RPHM N/A
- Revenue Growth
- IMMX N/A
- RPHM N/A
- 52 Week Low
- IMMX $1.26
- RPHM $1.68
- 52 Week High
- IMMX $7.75
- RPHM $92.10
- Technical
- Relative Strength Index (RSI)
- IMMX 41.10
- RPHM 18.64
- Support Level
- IMMX $1.44
- RPHM $16.10
- Resistance Level
- IMMX $1.80
- RPHM $19.00
- Average True Range (ATR)
- IMMX 0.16
- RPHM 1.09
- MACD
- IMMX 0.01
- RPHM -1.48
- Stochastic Oscillator
- IMMX 46.10
- RPHM 0.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About RPHM Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.